CEL — Celadon Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- £65.17m
- £68.23m
- £0.02m
2018 August 31st | 2019 August 31st | 2020 August 31st | R2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 16 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | — | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0.002 | 0.024 |
Cost of Revenue | |||||
Gross Profit | — | — | — | -2.39 | -4.92 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | — | 0.206 | 0.187 | 3.49 | 6.87 |
Operating Profit | 0 | -0.206 | -0.187 | -3.49 | -6.85 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | — | -0.191 | -0.175 | -4.8 | -18.1 |
Provision for Income Taxes | |||||
Net Income After Taxes | — | -0.191 | -0.175 | -4.78 | -17.4 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | — | -0.191 | -0.175 | -4.63 | -17 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 0 | -0.191 | -0.175 | -4.63 | -17 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | — | -0.029 | -0.028 | -0.093 | -0.28 |
Dividends per Share |